ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Trial Profile

ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2013

At a glance

  • Drugs MVA 3000 (Primary) ; MVA 3000 (Primary) ; MVA 3000 (Primary) ; Smallpox vaccine
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 Mar 2010 Dryvax challenge results published in the Journal of Infectious Diseases.
    • 10 Mar 2010 Immunogenicity and reactogenicity results published in the Journal of Infectious Diseases.
    • 18 Sep 2008 Primary end point identified as safety as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top